Recall: Blood pressure meds could contain carcinogen

January 3, 2019
Soaring drug prices are a growing concern for many, with an estimated 32 million people affected by at least one price hike in the last year.

The FDA is warning patients of another recall involving blood pressure medication and cancer-causing agents.

Aurobindo Pharma USA, Inc. is voluntarily recalling 80 lots of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP due to the detection of trace amounts of an impurity found in the finished drug product.

The issue is N-nitrosodiethylamine (NDEA), a substance that occurs naturally in certain foods, drinking water, air pollution and industrial processes and has been classified as a probable human carcinogen.

The tablets were distributed nationwide. Aurobindo Pharma USA, Inc. has not yet received any reports of illness in connection with the recall.

According to the FDA, patients currently taking the tablets listed in the recall should not stop taking their medication. The FDA said the health risk is higher if the treatment is stopped immediately without any alternative treatment.

Patients taking the medication should, however, contact their pharmacist or physician. Consumers with medical questions regarding this recall can contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or pvg@aurobindousa.com.

Update hourly